Find clinical trials for Pancreatic Cancer in Toronto, ON
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Toronto, ON, CAN:
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Toronto, Ontario, Canada and 15 other locations
phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety pr...
Phase 1
Toronto, Ontario, Canada and 71 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Toronto, Ontario, Canada and 29 other locations
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age....
Phase 1, Phase 2
Toronto, Ontario, Canada and 67 other locations
to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...
Phase 2
Toronto, Ontario, Canada and 63 other locations
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other ...
Phase 2
Toronto, Ontario, Canada and 15 other locations
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially d...
Phase 1, Phase 2
Toronto, Ontario, Canada and 13 other locations
of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid ...
Phase 2
Toronto, Ontario, Canada and 49 other locations
biliary cancer that has spread to other organs. It is hoped that this new combination of drugs (nab-paclitaxel, gemcitabine, and cisplatin)...
Phase 2
Toronto, Ontario, Canada and 1 other location
deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors.This study will consist of Part 1 which includes 7 cohorts of: uroth ...
Phase 2
Hamilton, Ontario, Canada and 120 other locations
Clinical trials
Research sites
Resources
Legal